Trillium Therapeutics Inc. Trillium Therapeutics Inc.
Thursday turned out to be a nightmare for Trillium Therapeutics Inc. (NASDAQ:TRIL) investors, after initial data for the company’s lead cancer drug TTI-621, which were released …
One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …
